Radiocopper in BCMA-targeted immunotheranostics of myeloma
Theranostics · 29.07.2026 · 16 (15) · 8461-8477
DOI: 10.7150/thno.134397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 29.07.2026. Verfasst von Martin Ullrich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, Bautz…. Hauptthemen laut MEDLINE: Multiple Myeloma, Copper Radioisotopes, B-Cell Maturation Antigen, Antibodies, Monoclonal. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background: The theranostic potential of copper-64 (PET imaging) and copper-67 (SPECT imaging and therapy) is increasingly recognized. This work investigates the performance of this 'true' matched pair in a preclinical radioimmunotheranostic setting that utilizes experimental monoclonal antibodies (mAbs) directed against B cell maturation antigen (BCMA), a transmembrane glycoprotein that has emerged as a critical target for the treatment of multiple myeloma (MM). Methods: enabling chelation of radiocopper, and their binding affinity was determined using surface plasmon resonance and flow cytometry. Pharmacokinetics and tumor uptake of the copper-64-labeled mAbs were determined in mice bearing subcutaneous myeloma xenografts, using PET. The best-performing mAb was included in a pilot study on therapeutic use with copper-67 in U266 myeloma-bearing mice, involving dose monitoring and dose predictions for humans based on quantitative SPECT. Results: -MAB193 delivered absorbed doses up to 1.26 Gy/MBq in U266 myeloma xenografts and reduced the tumor mass at total doses above 52 Gy. Predicted human effective doses were below 35.3 µSv/MBq for immunoPET and 162 µSv/MBq for radioimmunotherapy/immunoSPECT. Conclusion: approach into the further development of BCMA-targeted radioimmunotheranostic agents, including precise tailoring of their pharmacokinetic properties to the physical half-life of copper-67.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, Bautzner Landstrasse 400, D-01328 Dresden, Germany.
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Medicinal Radiochemistry, Bautzner Landstrasse 400, D-01328 Dresden, Germany.
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Resource Ecology, Department of Radiation Research on Biological Systems, Bautzner Landstrasse 400, D-01328 Dresden, Germany.
- Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, D-01062 Dresden, Germany.
Zitieren
APA
Ullrich, M., Zarschler, K., Kubeil, M., Laube, M., Pietzsch, J., & Belter, B. (2026). Radiocopper in BCMA-targeted immunotheranostics of myeloma. Theranostics, 16(15), 8461-8477. https://doi.org/10.7150/thno.134397
Vancouver
Ullrich M, Zarschler K, Kubeil M, Laube M, Pietzsch J, Belter B. Radiocopper in BCMA-targeted immunotheranostics of myeloma. Theranostics. 2026;16(15):8461-8477. doi:10.7150/thno.134397
BibTeX
@article{Ullrich2026,
author = {Ullrich, Martin and Zarschler, Kristof and Kubeil, Manja and Laube, Markus and Pietzsch, Jens and Belter, Birgit},
title = {Radiocopper in BCMA-targeted immunotheranostics of myeloma},
journal = {Theranostics},
year = {2026},
volume = {16},
number = {15},
pages = {8461--8477},
doi = {10.7150/thno.134397}
}
EUVIMED